From forgotten cure to modern medicine: The resurgence of bacteriophage therapy

Phage applications for biocontrol of enterohemorrhagic E. coli O157:H7 and other Shiga toxin-producing Escherichia coli

Foodborne outbreaks are becoming increasingly common and linked to zoonotic diseases caused by microbial spillover from wild or farm animals. Furthermore, agricultural animals could be considered reservoirs of multidrug-resistant (MDR) microorganisms. Escherichia coli O157:H7, a widespread foodborne pathogen, poses a substantial hazard due to its ubiquitous environmental distribution, MDR phenotypes, and life-threatening pathogenicity. This bacterium produces a potent toxin (Shiga toxin, Stx) encoded by prophages (Stx-phage). In addition to antibiotic resistance, E. coli O157:H7 has been shown to express more Stx upon treatment with antibiotics such as trimethoprim-sulfamethoxazole and metronidazole than controls. The combination of MDR and increased pathogenicity upon antibiotic treatment requires the development of alternatives for treating and preventing E. coli O157:H7 and related bacteria. Bacterial viruses (phages) are gaining popularity in clinical and veterinary settings due to their high antibacterial activities and lack of side effects in animals. Phage application in food production can help reduce the spread of E. coli O157:H7 and other Stx-producing E. coli (STEC), thus decreasing the burden of infection and economic loss due to these foodborne zoonoses. The present review will provide an update on phage utilization in the food industry to reduce the STEC load, with particular focus on O157:H7.

Isolation and Genomic Analysis of Escherichia coli Phage AUBRB02: Implications for Phage Therapy in Lebanon

BACKGROUND/OBJECTIVES

Escherichia coli (E. coli), a prevalent Gram-negative bacterium, is a frequent cause of illness. The extensive use of antibiotics has led to the emergence of resistant strains, complicating antimicrobial therapy and emphasizing the need for natural alternatives such as phages.

METHODS

In this study, a novel Escherichia coli phage, AUBRB02, was isolated from sewage and characterized through whole-genome sequencing, host range assays, and biofilm elimination assays. The phage's stability and infectivity were assessed under various pH and temperature conditions, and different E. coli strains.

RESULTS

Phage AUBRB02 has an incubation period of 45 min, a lysis period of 10 min, and a burst size of 30 phages/infected cell. It is stable across pH 5.0-9.0 and temperatures from 4 °C to 60 °C. Treatment with AUBRB02 significantly reduced post-formation E. coli biofilms, as indicated by lower OD values compared with the positive control. The whole genome sequencing revealed a genome size of 166,871 base pairs with a G + C (Guanine and Cytosine content) content of 35.47%. AUBRB02 belongs to the Tequatrovirus genus, sharing 93% intergenomic similarity with its closest RefSeq relative, and encodes 262 coding sequences, including 10 tRNAs.

CONCLUSIONS

AUBRB02 demonstrates high infectivity and stability under diverse conditions. Its genomic features and similarity to related phages highlight its potential for phage therapy, offering promising prospects for the targeted treatment of E. coli infections.

Characterization of a novel lytic phage vB_AbaM_AB4P2 encoding depolymerase and its application in eliminating biofilms formed by Acinetobacter baumannii

BACKGROUND

Acinetobacter baumannii strains are a primary cause of hospital-acquired infections. This bacterium frequently causes biofilm-related infections, notably ventilator-associated pneumonia and catheter-related infections, which exhibit remarkable resistance to antibiotic treatment, posing a severe challenge in the prevention of A. baumannii infections. Therefore, strategies to eliminate the biofilm of A. baumannii in catheters are becoming increasingly important. Phages are capable of lysing bacteria and have a certain effect on the ablation of biofilms.

METHODS

Sewage treatment plant water was collected for the isolation of A. baumannii phages. The morphological, host range, one-step growth, temperature and pH stability, bactericidal activity, sequencing and genomic analysis were performed to characterize the isolated phage. The three-dimensional structure of the tail fiber protein was predicted by AlphaFold3. The efficacy of phage in clearing biofilms of A. baumannii from 24-well plates and PVC catheters was also evaluated.

RESULTS

In this study, A. baumannii lytic phage vB_AbaM_AB4P2 was isolated from sewage treatment plant water, showing a clear plaque with halo zone. One-step growth assays unveiled a 20-minute latent period and a burst size of 61 plaque forming unit/cell (PFU/cell). At the same time, phage AB4P2 exhibited remarkable stability at pH 3-11 and temperatures 30-70 °C. Its dsDNA genome is composed of 45,680 bp with a G + C content of 46.13%. Genomic and phylogenetic analysis situated phage AB4P2 as a new species of Caudoviricetes class. Its fiber protein possesses a pectin lyase-like domain that is linked to depolymerase activity, playing a crucial role in disrupting biofilms. Additionally, it also encodes a lysis cassette comprising endolysin, holin and Rz-like spanin, yet lacks any genes responsible for antibiotic resistance and virulence factors. Phage AB4P2 can completely inhibit A. baumannii growth for 16 h. In the 24-well plate and the polyvinyl chloride (PVC) catheter model experiments, phage AB4P2 achieved a significant biofilm ablation rate and effectively killed the live bacterial cells in the biofilm.

CONCLUSIONS

Phage AB4P2 had good environmental stability and strong ability to inhibit the growth of A. baumannii and destroy formed biofilms by A. baumannii. It exhibits promising potential for development as an alternative environmental disinfectant against A. baumannii in the hospital.

CLINICAL TRIAL NUMBER

Not applicable.